Related Experiment Videos
Effects of sulindac on myeloid precursors growth in vitro
Methods and Findings in Experimental and Clinical Pharmacology
|February 1, 1984
Abstract:
We have studied the effects of sulindac and its main active metabolites on human bone marrow progenitors. Granulocytic-macrophagic colony forming units (CFU-GM) techniques were used for assessment. As in vitro inhibitory action of this drug or its metabolites on CFU-GM growth could not be demonstrated. These results refute the clinically presumed toxicity of sulindac on human bone marrow progenitors at pharmacological doses.
Insights
This study investigated sulindac
Area of Science:
- Pharmacology
- Hematology
- Toxicology
Background:
- Sulindac is a nonsteroidal anti-inflammatory drug (NSAID).
- Clinical use of sulindac has raised concerns about potential bone marrow toxicity.
- The effects of sulindac on human bone marrow progenitors require detailed investigation.
Purpose of the Study:
- To evaluate the in vitro effects of sulindac and its active metabolites on human bone marrow progenitors.
- To determine if sulindac or its metabolites inhibit the growth of granulocytic-macrophagic colony-forming units (CFU-GM).
Main Methods:
- Human bone marrow progenitor cells were isolated.
- Granulocytic-macrophagic colony-forming units (CFU-GM) assay was employed.
- Cells were exposed to sulindac and its active metabolites in vitro.
Main Results:
- No significant inhibitory effect of sulindac or its metabolites on CFU-GM growth was observed.
- In vitro assessment did not demonstrate sulindac-induced toxicity on bone marrow progenitor cells.
Conclusions:
- The findings suggest that sulindac is not toxic to human bone marrow progenitors at pharmacological doses.
- This study refutes the presumed clinical toxicity of sulindac on bone marrow.
- Further research may explore the mechanisms underlying the safety profile of sulindac in vivo.